Chase Pharmaceuticals

United States Founded: 2007 • Age: 19 yrs Acquired By Allergan
Developer of drugs improve cognition and behavioral symptoms associated with Alzheimers disease

About Chase Pharmaceuticals

Chase Pharmaceuticals is a Healthcare company based in United States founded in 2007, and was acquired by Allergan in November 2016. Developer of drugs improve cognition and behavioral symptoms associated with Alzheimers disease. Chase Pharmaceuticals has raised $37.67 million across 7 funding rounds from investors including Cipla, Edmond de Rothschild and Allergan. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its competitors include T3D Therapeutics, Alzheon and Longeveron; 3 of its 3 listed competitors have raised funding.

Company details

Developer of drugs improves cognition and behavioral symptoms associated with Alzheimers disease. The companys candidates include CPC-201, CPC-212, and CPC-250 which are next-generation Acetylcholinesterase inhibitors (AChEI) formulations for the symptomatic treatment of Alzheimers disease.

Operational Areas
Key Metrics
  • Total Equity Funding
    $37.67M (USD)

    in 7 rounds

  • Investors
    Cipla

    & 4 more

  • Acquired by
    Allergan

    (Nov 2016)

Funding Insights of Chase Pharmaceuticals

Chase Pharmaceuticals has successfully raised a total of $37.67M across 7 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $37.67M
  • Total Rounds 7
  • Investors Count 4

All 7 funding rounds of Chase Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Nov 2016Series B––
Mar 2016$11.97MSeries B––
–
Feb 2016$3.5MSeries B–Cipla
May 2014$21MSeries B–New Rhein
Jun 2011Series A–Brain Trust Accelerator Fund
–
Nov 2010$1.2MSeries A––
–
Jun 2010Series A–Brain Trust Accelerator Fund
–
Valuation history

5 investors in total: 5 institutional.

Investors in Chase Pharmaceuticals

Chase Pharmaceuticals has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Cipla, Edmond de Rothschild and Allergan.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Healthcare investments are focused on life sciences ventures.
newrhein.comPhiladelphia, USA
Diversified asset management, corporate advisory, and private equity firm focused on multiple sectors
1953edmond-de-rothschild.comParis, France
Investment fund focused on brain disease diagnosis and treatment.
braintrustvc.comBurlingame, United States
APIs, generic drugs, and formulation services are manufactured.
1935cipla.comMumbai, India
A portfolio of generic medicines is developed and manufactured.
1948allergan.comMadison, United States
Premium access

Investor details for Chase Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Chase Pharmaceuticals

4 dated milestones of Chase Pharmaceuticals across 9 years, from founding to its latest funding, stage changes and deals.

  1. Founded Chase Pharmaceuticals is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Series B,.
  4. Exit Acquired by Allergan.

Competitors of Chase Pharmaceuticals

Chase Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include T3D Therapeutics, Alzheon and Longeveron.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
t3dtherapeutics.com2013Durham, United States$33.02M
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
alzheon.com2013Framingham, United States$195.25M
Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed.
longeveron.com2014Miami, United States$1.05M23
Cellular therapies for aging-related and life-threatening conditions are developed.
Premium access

Detailed competitors of Chase Pharmaceuticals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Neurology

3 companies that operate in the same segment as Chase Pharmaceuticals (Neurology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Developer of therapeutics for psychiatric and neurologic diseases
2002New York, New York, United StatesUSD 80.87 MUSD 250.31 M600
Biologics platform developed for intracellular delivery in rare diseases.
2016Boston, Massachusetts, United StatesUSD 175.25 MUSD 25.42 M183
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Chase Pharmaceuticals

Premium access

Complete news archive for Chase Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Chase Pharmaceuticals

Chase Pharmaceuticals was founded in 2007 and raised its 1st funding round 3 years after it was founded.

Chase Pharmaceuticals is headquartered in United States.

Chase Pharmaceuticals is a funded company, having raised a total of $37.67M across 7 funding rounds to date.

Developer of drugs improves cognition and behavioral symptoms associated with Alzheimers disease. The companys candidates include CPC-201, CPC-212, and CPC-250 which are next-generation Acetylcholinesterase inhibitors (AChEI) formulations for the symptomatic treatment of Alzheimers disease.

Chase Pharmaceuticals's top competitors include Alzheon, Longeveron and T3D Therapeutics.

Chase Pharmaceuticals has 5 investors. Key investors include Cipla, Edmond de Rothschild, Allergan, New Rhein Healthcare Investors, and Brain Trust Accelerator Fund.

Yes. Chase Pharmaceuticals was acquired by Allergan in November 2016.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available